Market Summary
USD78.56+0.75
Market Closed0.96%
GILD Stock Price
GILD RSI Chart
GILD Valuation
GILD Price/Sales (Trailing)
GILD Profitability
GILD Fundamentals
GILD Revenue
GILD Earnings
Price Action
52 Week Range
56.0689.29
(Low)(High)
Last 7 days
-1.6%
Last 30 days
-7.2%
Last 90 days
-7.3%
Trailing 12 Months
37.8%
GILD Financial Health
GILD Investor Care
Peers (Alternatives to Gilead Sciences)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 124.2B | 26.3B | -2.34% | 1.62% | 18.96 | 4.72 | 1.32% | 11.18% |
GILD | 98.0B | 27.3B | -7.18% | 37.83% | 21.33 | 3.59 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | -7.28% | -16.95% | 6.83 | 2.97 | 4.29% | -31.47% |
BIIB | 38.1B | 10.2B | -3.01% | 25.82% | 12.5 | 3.74 | -7.36% | 95.80% |
| MID-CAP | ||||||||
NBIX | 9.2B | 1.5B | -6.54% | 2.94% | 59.61 | 6.19 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -20.63% | -31.77% | -9.51 | 28.59 | 122.90% | -12.19% |
BEAM | 2.2B | 60.9M | -22.54% | -46.32% | -7.52 | 35.66 | 17.51% | 22.00% |
BBIO | 1.9B | 107.9M | 7.80% | 19.42% | -3.99 | 17.93 | 54.84% | 17.36% |
| SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -12.49% | -50.70% | -4.44 | 10.58 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -19.12% | 19.58% | -7.01 | 156.87 | 131.81% | -45.39% |
FATE | 507.9M | 96.3M | -13.43% | -85.87% | -1.8 | 5.27 | 72.44% | -32.79% |
NVAX | 499.9M | 2.0B | -38.13% | -92.75% | -0.76 | 0.25 | 72.89% | 62.27% |
SGMO | 278.5M | 111.3M | -41.20% | -71.01% | -1.45 | 2.5 | 0.54% | -7.86% |
VXRT | 98.0M | 107.0K | -22.42% | -85.54% | -0.91 | 915.57 | -88.00% | -52.91% |
IBIO | 26.6M | - | 29.52% | -80.89% | -0.33 | 3.21 | 0.51% | -185.61% |
Financials for Gilead Sciences
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 0.5% | 27,281 | 27,136 | 27,515 | 27,472 | 27,305 |
| S&GA Expenses | 7.0% | 5,673 | 5,303 | 5,280 | 5,274 | 5,246 |
| Costs and Expenses | -5.6% | 19,951 | 21,133 | 20,507 | 20,247 | 17,387 |
| EBITDA | 21.5% | 7,072 | 5,819 | 6,848 | 7,175 | - |
| EBITDA Margin | 20.9% | 0.26* | 0.21* | 0.25* | 0.26* | - |
| Earnings Before Taxes | 28.0% | 5,814 | 4,542 | 5,548 | 5,862 | 8,278 |
| EBT Margin | 27.3% | 0.21* | 0.17* | 0.20* | 0.21* | - |
| Interest Expenses | -1.3% | 935 | 947 | 968 | 982 | 1,001 |
| Net Income | 37.7% | 4,592 | 3,334 | 4,137 | 4,515 | 6,225 |
| Net Income Margin | 37.0% | 0.17* | 0.12* | 0.15* | 0.16* | - |
| Free Cahsflow | -7.4% | 8,344 | 9,007 | 9,415 | 9,953 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 1.0% | 63,171 | 62,557 | 62,870 | 63,080 | 67,952 |
| Current Assets | 6.6% | 14,443 | 13,554 | 13,175 | 12,629 | 14,772 |
| Cash Equivalents | 15.2% | 5,412 | 4,699 | 4,739 | 4,296 | 5,338 |
| Inventory | 3.0% | 1,507 | 1,463 | 1,494 | 1,482 | 1,618 |
| Net PPE | 2.4% | 5,475 | 5,349 | 5,299 | 5,253 | 5,121 |
| Goodwill | 0% | 8,314 | 8,314 | 8,314 | 8,314 | 8,332 |
| Current Liabilities | 7.8% | 11,237 | 10,423 | 9,220 | 8,558 | 11,610 |
| Long Term Debt | -3.8% | 25,223 | 26,216 | 26,208 | 26,695 | - |
| LT Debt, Current | 122.3% | 2,270 | 1,021 | 1,025 | 1,516 | - |
| LT Debt, Non Current | 0.0% | 22,957 | 22,953 | 25,195 | 25,183 | 25,179 |
| Shareholder's Equity | 0.8% | 21,240 | 21,081 | 20,215 | 19,915 | 21,069 |
| Retained Earnings | -0.4% | 15,687 | 15,756 | 15,117 | 14,986 | 16,324 |
| Additional Paid-In Capital | 6.2% | 5,550 | 5,226 | 5,031 | 4,867 | 4,661 |
| Accumulated Depreciation | - | 1,893 | - | - | - | - |
| Shares Outstanding | -0.6% | 1,247 | 1,254 | 1,254 | 1,255 | 1,254 |
| Minority Interest | -29.2% | -31.00 | -24.00 | -21.00 | -12.00 | -5.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -6.6% | 9,072 | 9,710 | 10,100 | 10,614 | 11,384 |
| Share Based Compensation | 2.4% | 637 | 622 | 625 | 626 | 635 |
| Cashflow From Investing | -4.1% | -2,466 | -2,369 | -1,890 | -2,159 | -3,131 |
| Cashflow From Financing | 5.7% | -6,469 | -6,857 | -8,266 | -8,194 | -8,877 |
| Dividend Payments | 0.6% | 3,709 | 3,688 | 3,659 | 3,633 | 3,605 |
| Buy Backs | 95.8% | 1,396 | 713 | 668 | 633 | 546 |
Risks for GILD
What is the probability of a big loss on GILD?
51.9%
Probability that Gilead Sciences stock will be more than 20% underwater in next one year
0%
Probability that Gilead Sciences stock will be more than 30% underwater in next one year.
0%
Probability that Gilead Sciences stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does GILD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Gilead Sciences was unfortunately bought at previous high price.
Drawdowns
Returns for GILD
Cumulative Returns on GILD
8.5%
10-Year Cumulative Returns
1.3%
7-Year Cumulative Returns
5.4%
5-Year Cumulative Returns
6.7%
3-Year Cumulative Returns
What are the long-term rolling returns for GILD?
FIve years rolling returns for Gilead Sciences.
Annualized Returns
Which funds bought or sold GILD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 23.48 | 1,068,530 | 2,560,530 | 0.07% |
2023-03-13 | Claro Advisors LLC | reduced | -13.93 | 73,231 | 445,231 | 0.15% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -5.9 | 47,911,600 | 202,688,000 | 0.22% |
2023-03-10 | MATHER GROUP, LLC. | added | 1.48 | 225,887 | 772,887 | 0.01% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -3.95 | 517,194 | 2,052,190 | 0.32% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -14.87 | 113,665 | 621,665 | 0.05% |
2023-03-06 | OLD MISSION CAPITAL LLC | sold off | -100 | -448,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -35.6 | -1,266,000 | 10,922,000 | 0.06% |
2023-03-03 | TIAA, FSB | reduced | -76.76 | -8,940,820 | 4,273,180 | 0.02% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 1,427,510 | 1,427,510 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Gilead Sciences News
Schedule 13G FIlings of Gilead Sciences
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital research global investors | 4.4% | 54,602,952 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 5.5% | 68,900,998 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 8.93% | 112,038,324 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 10.5% | 131,555,769 | SC 13G/A | |
| Jul 08, 2022 | blackrock inc. | 10.1% | 126,932,693 | SC 13G | |
| Feb 11, 2022 | capital research global investors | 8.5% | 107,156,981 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 8.43% | 105,803,799 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.5% | 118,961,206 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 9.7% | 121,672,399 | SC 13G/A |
GILD Fair Value
Gilead Sciences fair value in different scenarios
The table shows the Fair Value estimates for Gilead Sciences for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 21.64 -72.45% | 27.25 -65.31% | 43.63 -44.46% | 72.06 -8.27% | 87.89 11.88% |
| Current Inflation | 20.58 -73.80% | 25.77 -67.20% | 40.40 -48.57% | 63.07 -19.72% | 76.28 -2.90% |
| Very High Inflation | 19.20 -75.56% | 23.86 -69.63% | 36.36 -53.72% | 52.66 -32.97% | 62.94 -19.88% |
Historical Gilead Sciences Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Gilead Sciences
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 14, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 4 | Insider Trading | |
| Mar 13, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 09, 2023 | 3 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for GILD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-13 | Parsey Merdad | sold | -483,893 | 78.99 | -6,126 | chief medical officer |
2023-03-10 | O'Day Daniel Patrick | acquired | - | - | 30,288 | chairman & ceo |
2023-03-10 | Parsey Merdad | sold (taxes) | -423,576 | 79.5 | -5,328 | chief medical officer |
2023-03-10 | Patterson Sandra | sold (taxes) | -63,679 | 79.5 | -801 | svp, controllership |
2023-03-10 | Patterson Sandra | acquired | - | - | 2,921 | svp, controllership |
2023-03-10 | Parsey Merdad | acquired | - | - | 11,454 | chief medical officer |
2023-03-10 | O'Day Daniel Patrick | sold (taxes) | -1,114,350 | 79.5 | -14,017 | chairman & ceo |
2023-03-10 | Dickinson Andrew D | sold (taxes) | -385,496 | 79.5 | -4,849 | chief financial officer |
2023-03-10 | Mercier Johanna | acquired | - | - | 10,976 | chief commercial officer |
2023-03-10 | Mercier Johanna | sold (taxes) | -406,722 | 79.5 | -5,116 | chief commercial officer |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 27,281 | $ 27,305 | $ 24,689 |
| Costs and expenses: | |||
| Cost of goods sold | 5,657 | 6,601 | 4,572 |
| Research and development expenses | 4,977 | 4,601 | 4,927 |
| Acquired in-process research and development expenses | 944 | 939 | 5,968 |
| In-process research and development impairment | 2,700 | 0 | 0 |
| Selling, general and administrative expenses | 5,673 | 5,246 | 5,151 |
| Total costs and expenses | 19,951 | 17,387 | 20,618 |
| Operating income | 7,330 | 9,918 | 4,071 |
| Interest expense | (935) | (1,001) | (984) |
| Other income (expense), net | (581) | (639) | (1,418) |
| Income before income taxes | 5,814 | 8,278 | 1,669 |
| Income tax expense | (1,248) | (2,077) | (1,580) |
| Net income | 4,566 | 6,201 | 89 |
| Net loss attributable to noncontrolling interest | 26 | 24 | 34 |
| Net income attributable to Gilead | $ 4,592 | $ 6,225 | $ 123 |
| Basic earnings per share attributable to Gilead (in dollars per share) | $ 3.66 | $ 4.96 | $ 0.10 |
| Shares used in basic earnings per share attributable to Gilead calculation (in shares) | 1,255 | 1,256 | 1,257 |
| Diluted earnings per share attributable to Gilead (in dollars per share) | $ 3.64 | $ 4.93 | $ 0.10 |
| Shares used in diluted earnings per share attributable to Gilead calculation (in shares) | 1,262 | 1,262 | 1,263 |
| Product sales | |||
| Revenues: | |||
| Total revenues | $ 26,982 | $ 27,008 | $ 24,355 |
| Royalty, contract and other revenues | |||
| Revenues: | |||
| Total revenues | $ 299 | $ 297 | $ 334 |
GILD Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 5,412 | $ 5,338 |
| Short-term marketable debt securities | 973 | 1,182 |
| Accounts receivable, net | 4,777 | 4,493 |
| Inventories | 1,507 | 1,618 |
| Prepaid and other current assets | 1,774 | 2,141 |
| Total current assets | 14,443 | 14,772 |
| Property, plant and equipment, net | 5,475 | 5,121 |
| Long-term marketable debt securities | 1,245 | 1,309 |
| Intangible assets, net | 28,894 | 33,455 |
| Goodwill | 8,314 | 8,332 |
| Other long-term assets | 4,800 | 4,963 |
| Total assets | 63,171 | 67,952 |
| Current liabilities: | ||
| Accounts payable | 905 | 705 |
| Accrued rebates | 3,479 | 3,244 |
| Other current liabilities | 4,580 | 6,145 |
| Current portion of long-term debt and other obligations, net | 2,273 | 1,516 |
| Total current liabilities | 11,237 | 11,610 |
| Long-term debt, net | 22,957 | 25,179 |
| Long-term income taxes payable | 3,916 | 4,767 |
| Deferred tax liability | 2,673 | 4,356 |
| Other long-term obligations | 1,179 | 976 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
| Common stock, par value $0.001 per share; 5,600 authorized; 1,247 and 1,254 shares issued and outstanding, respectively | 1 | 1 |
| Additional paid-in capital | 5,550 | 4,661 |
| Accumulated other comprehensive income | 2 | 83 |
| Retained earnings | 15,687 | 16,324 |
| Total Gilead stockholders’ equity | 21,240 | 21,069 |
| Noncontrolling interest | (31) | (5) |
| Total stockholders’ equity | 21,209 | 21,064 |
| Total liabilities and stockholders’ equity | $ 63,171 | $ 67,952 |